Conversely, inhibition of TGFbeta/Activin signaling using a specific inhibitor of the type I Activin receptor (ALK-I) resulted in rapid FGF-iPSC differentiation, while this inhibitor did not affect mESC self-renewal (Fig. 6).
Screening for compounds that are active in later stages identified two kinase inhibitors ALK-i I and ALK-i II, which guided the differentiation of pancreatic progenitors to functionally mature endocrine glucose-responsive α cells [ 15].
Next, we investigated expression and phosphorylation levels of proteins involved in ALK signaling (i.e. AKT, ERK1/2 and STAT3).
We found that alk-BthTX-I and alk-BthTX-II reduce the lethal dose (LD50) relative to that of BthTX-I and BthTX-II.
The electrophoretic profile in SDS-PAGE showed that alk-BthTX-I and alk-BthTX-II did not present differences when compared with the native BthTX-I and BthTX-II forms).
While conducting postdoctoral studies to identify and modulate the activity of the NPM-ALK oncogene, I practiced and developed the skills necessary to explain the relevance of my work to lay people and nonspecialist scientists.
Messenger RNAs for BMP-2, -4, -7, the BMP type I receptors Act R-I (alk 2, activin-like kinase receptor), BMPR-IA (alk 3), -IB (alk 6), and the type II receptor BMPR-II were detected.
However, we judged these cases positive for ALK fusion because (i) all the cancer cells clearly showed ALK expression by IHC (iScore 3; Figure 3B and I); (ii) both cases showed a mucinous cribriform pattern on histopathological analysis, which is the characteristic of ALK+ LC [ 10]; and (iii) the ALK locus was indeed rearranged although the observed FISH pattern was atypical.
The 3.0 Kb fragment, containing the alkB gene cluster, was then amplified by PCR using the primers Nco I-alk R7 5′-AAGGCCATGGACGTGACGACGTCGGATATC-3′ aNdeNde I-alk R7 5′-ACAGCATATGACCTAGCGGGCGGCCGCGAC-3′ in order to generate the Nco I-Nde I ends.
Like most Activin/TGF- β family members, myostatin binds to the cell surface activin receptor II or IIB (ACTRII, ACTRIIB), which recruits type I receptor ALK 4/5 (Activin receptor-like kinase 4 or 5) to form a complex.
Cell sensitivity to the peptide was dependent on ALK expression by tumor cells as: (i) ALK-negative tumor cells failed to respond and (ii) expressing either NPM ALK or full-length ALK restored P36-responsiveness of lymphoma or neuroblastoma cells, respectively.
